gefitinib has been researched along with butylhydroxybutylnitrosamine in 2 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (butylhydroxybutylnitrosamine) | Trials (butylhydroxybutylnitrosamine) | Recent Studies (post-2010) (butylhydroxybutylnitrosamine) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 557 | 1 | 80 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akaza, H; Hattori, K; Iida, K; Joraku, A; Oyasu, R; Tsukamoto, S | 1 |
| Bode, AM; Grubbs, CJ; Juliana, MM; Lu, Y; Lubet, RA; Steele, VE; Townsend, R; Verney, ZM; You, M | 1 |
2 other study(ies) available for gefitinib and butylhydroxybutylnitrosamine
| Article | Year |
|---|---|
Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Carcinogens; Carcinoma, Transitional Cell; Cyclooxygenase Inhibitors; Gefitinib; Male; Meloxicam; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Inbred F344; Thiazines; Thiazoles; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers.
Topics: Animals; Antineoplastic Agents; Biomarkers; Butylhydroxybutylnitrosamine; Cluster Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Models, Biological; Quinazolines; Rats; Signal Transduction; Urinary Bladder Neoplasms | 2011 |